Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 706

Results For "X"

9483 News Found

Lupin and DKSH sign licensing and supply agreement to market five biosimilar candidates in the Philippines
News | September 07, 2022

Lupin and DKSH sign licensing and supply agreement to market five biosimilar candidates in the Philippines

Lupin’s subsidiary in Philippines, Multicare Pharmaceuticals, will file for marketing approval and be responsible for distribution and commercialization of the biosimilars once approved.


Mandaviya virtually lays Foundation Stone of NCDC branches in 6 states
Policy | September 07, 2022

Mandaviya virtually lays Foundation Stone of NCDC branches in 6 states

NCDC branches in States/UTs will provide a boost to Public Health Infrastructurewith prompt surveillance, rapid detection and timely monitoring of diseases enabling Early Interventions


Lonza and Touchlight collaborate on end-to-end mRNA offering
Biotech | September 07, 2022

Lonza and Touchlight collaborate on end-to-end mRNA offering

Under the terms of the agreement, Lonza can now provide its customers with seamless access to Touchlight’s enzymatic DNA technology


Artemis Hospitals opens new centre Daffodils by Artemis in Jaipur
Healthcare | September 06, 2022

Artemis Hospitals opens new centre Daffodils by Artemis in Jaipur

Daffodils by Artemis is a premiere luxury birthing centre offering mother and child care services.


Boehringer Ingelheim InPedILD Phase III trial showed encouraging results for both primary endpoints
Clinical Trials | September 06, 2022

Boehringer Ingelheim InPedILD Phase III trial showed encouraging results for both primary endpoints

New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease


InnoCare announces priority review of Orelabrutinib for the treatment of R/R MZL by NMPA
News | September 06, 2022

InnoCare announces priority review of Orelabrutinib for the treatment of R/R MZL by NMPA

Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.


Aurionpro acquires US based startup Hello Patients
News | September 06, 2022

Aurionpro acquires US based startup Hello Patients

Hello Patients provides healthcare billing and patients’ management solution


AstraZeneca partners with Alveofit to scale up the diagnosis and treatment of lung diseases in India
News | September 05, 2022

AstraZeneca partners with Alveofit to scale up the diagnosis and treatment of lung diseases in India

This partnership aims to embed latest technological advancements in diagnosing and managing lung disorders and associated non-communicable diseases like asthma, pulmonary fibrosis and COPD.


Pfizer and BioNTech receive positive CHMP opinion for Omicron BA.1-adapted bivalent COVID-19 vaccine booster in EU
News | September 05, 2022

Pfizer and BioNTech receive positive CHMP opinion for Omicron BA.1-adapted bivalent COVID-19 vaccine booster in EU

CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccine


Yingli Pharma announces first patient dosed in Phase 2 Trial of Linperlisib for peripheral T Cell Lymphoma
Clinical Trials | September 05, 2022

Yingli Pharma announces first patient dosed in Phase 2 Trial of Linperlisib for peripheral T Cell Lymphoma

Phase 2 study to assess efficacy and safety of once daily linperlisib in patients with advanced peripheral T/NK cell lymphoma